Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Stephen L. Sabba sold 622 shares of the company’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $180.73, for a total value of $112,414.06. Following the transaction, the director now directly owns 26,363 shares of the company’s stock, valued at $4,764,584.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Ligand Pharmaceuticals Inc. (LGND) traded down $4.52 on Tuesday, reaching $178.10. The company had a trading volume of 369,748 shares, compared to its average volume of 313,325. Ligand Pharmaceuticals Inc. has a fifty-two week low of $102.56 and a fifty-two week high of $184.79. The company has a market capitalization of $3,760.00, a price-to-earnings ratio of 349.22, a PEG ratio of 1.78 and a beta of 1.10. The company has a quick ratio of 0.97, a current ratio of 0.99 and a debt-to-equity ratio of 0.05.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.12. Ligand Pharmaceuticals had a return on equity of 14.44% and a net margin of 8.90%. The business had revenue of $50.50 million for the quarter, compared to analyst estimates of $49.39 million. During the same quarter in the prior year, the company posted $1.25 earnings per share. Ligand Pharmaceuticals’s revenue was up 32.2% on a year-over-year basis. equities research analysts anticipate that Ligand Pharmaceuticals Inc. will post 3.59 earnings per share for the current year.
Several research firms have recently weighed in on LGND. BidaskClub raised Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 8th. HC Wainwright upped their price objective on Ligand Pharmaceuticals from $170.00 to $182.00 and gave the stock a “buy” rating in a research report on Wednesday, March 7th. Craig Hallum reaffirmed a “buy” rating and set a $200.00 price objective (up from $190.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, March 7th. TheStreet cut Ligand Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Thursday, March 1st. Finally, Zacks Investment Research raised Ligand Pharmaceuticals from a “hold” rating to a “buy” rating and set a $171.00 price objective for the company in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Ligand Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $161.00.
TRADEMARK VIOLATION WARNING: This report was first published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.themarketsdaily.com/2018/03/14/ligand-pharmaceuticals-inc-lgnd-director-sells-112414-06-in-stock.html.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.